Wilson HTM today released a research and valuation report on Anatara Lifesciences (ANR). The report initiated a Speculative BUY rating and a price target of 60 cps.

Bull case valuations can push north of $2.50 per share if project success and international marketing partners are delivered over the next few years.”

Please open the attached PDF to view the report.